2022
296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Wu Y, Tsuboi M, Grohe C, John T, Tarruella M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Herbst R. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. Annals Of Oncology 2022, 33: s1548-s1549. DOI: 10.1016/j.annonc.2022.10.324.Peer-Reviewed Original ResearchLBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
John T, Grohe C, Goldman J, De Marinis F, Kato T, Wang Q, Choi J, Melotti B, Fidler M, Sainsbury L, Stachowiak M, Taggart S, Wu Y, Tsuboi M, Herbst R, Tarruella M. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA. Annals Of Oncology 2022, 33: s1548. DOI: 10.1016/j.annonc.2022.10.323.Peer-Reviewed Original ResearchLBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Tsuboi M, Wu Y, Grohe C, John T, Tarruella M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Herbst R. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. Annals Of Oncology 2022, 33: s1413-s1414. DOI: 10.1016/j.annonc.2022.08.047.Peer-Reviewed Original Research
2021
OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
Majem M, Goldman J, John T, Grohe C, Laktionov K, Kim S, Kato T, Vu H, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst R, Wu Y. OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC. Journal Of Thoracic Oncology 2021, 16: s112-s113. DOI: 10.1016/j.jtho.2021.01.291.Peer-Reviewed Original Research
2020
356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Tsuboi M, Wu Y, He J, John T, Grohe C, Majem M, Goldman J, Laktionov K, Kim S, Kato T, Vu H, Akewanlop C, Yu C, de Marinis F, Domine M, Shepherd F, Yan C, Atasoy A, Herbst R. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. Annals Of Oncology 2020, 31: s1378. DOI: 10.1016/j.annonc.2020.10.349.Peer-Reviewed Original ResearchOsimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Tsuboi M, Wu Y, He J, John T, Grohe C, Majem M, Goldman J, Laktionov K, Kim S, Kato T, Vu H, Akewanlop C, Yu C, de Marinis F, Domine M, Shepherd F, Yan C, Atasoy A, Herbst R. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. Annals Of Oncology 2020, 31: s1177. DOI: 10.1016/j.annonc.2020.08.2279.Peer-Reviewed Original Research
2017
P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers
Rothberg B, Das R, Jackson L, Lazowski H, Bai Y, O'Neill D, Roberts S, Rothberg J, Herbst R, Kim A, Boffa D, Rimm D, Detterbeck F, Tanoue L. P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers. Journal Of Thoracic Oncology 2017, 12: s623-s624. DOI: 10.1016/j.jtho.2016.11.801.Peer-Reviewed Original Research
2011
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma. Journal Of Clinical Investigation 2011, 121: 1313-1328. PMID: 21436589, PMCID: PMC3070607, DOI: 10.1172/jci42405.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedApoptosisBevacizumabCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsGene Expression ProfilingHumansLung NeoplasmsMaleMiceMice, NudeNeovascularization, PathologicRNA, MessengerRNA, NeoplasmStromal CellsUp-RegulationVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysConceptsMouse xenograft modelHuman lung adenocarcinomaTumor cellsPrimary resistanceLung adenocarcinomaXenograft modelFGFR pathwayProgression-free survivalVEGF inhibitor bevacizumabEndothelium of tumorsInhibitors of angiogenesisCombination regimensTreatment of cancerVEGF inhibitorsPericyte coverageAntiangiogenic therapyVascular remodelingAngiogenesis inhibitorsTherapeutic efficacyTumor growthStromal pathwaysClinical useEGFRAcquired ResistanceEGFR pathway
2010
BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)
Hong W, Herbst R, Kim E. BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination). 2010 DOI: 10.21236/ada542458.Peer-Reviewed Original Research
2007
A5-02: Targeted therapy against VEGFR and/or EGFR signaling with AZD2171, vandetanib, and gefitinib as part of a combined modality approach for the treatment of non-small-cell lung cancer
O'Reilly M, Furutani K, Wu W, Onn A, Ryan A, Jürgensmeier J, Komaki R, Herbst R. A5-02: Targeted therapy against VEGFR and/or EGFR signaling with AZD2171, vandetanib, and gefitinib as part of a combined modality approach for the treatment of non-small-cell lung cancer. Journal Of Thoracic Oncology 2007, 2: s323. DOI: 10.1097/01.jto.0000283119.37036.8c.Peer-Reviewed Original Research
2005
O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib
Eberhard D, Johnson B, Goddard A, Herbst R, Janne P, Johnson D, Klein P, Ostland M, Seshagiri S, Hillan K. O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib. Lung Cancer 2005, 49: s62. DOI: 10.1016/s0169-5002(05)80320-4.Peer-Reviewed Original Research
2004
Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer
SHIBUYA K, KOMAKI R, WU W, SHINTANI T, ITASAKA S, ISOBE T, RYAN A, HERBST R, OREILLY M. Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. International Journal Of Radiation Oncology • Biology • Physics 2004, 60: s149-s150. DOI: 10.1016/s0360-3016(04)01118-6.Peer-Reviewed Original ResearchTargeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer
Shibuya K, Komaki R, Wu W, Shintani T, Itasaka S, Isobe T, Ryan A, Herbst R, O’Reilly M. Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. International Journal Of Radiation Oncology • Biology • Physics 2004, 60: s149-s150. DOI: 10.1016/j.ijrobp.2004.06.061.Peer-Reviewed Original Research
2001
Epidermal growth factor receptor biology (IMC-C225)
Kim E, Khuri F, Herbst R. Epidermal growth factor receptor biology (IMC-C225). Current Opinion In Oncology 2001, 13: 506-513. PMID: 11673692, DOI: 10.1097/00001622-200111000-00014.Peer-Reviewed Original ResearchConceptsIMC-C225Epidermal growth factor receptor biologyMonoclonal antibodiesLigand-linked toxinsOverall clinical outcomeOverall poor prognosisTyrosine kinase inhibitorsTyrosine kinase inhibitionOverexpression of EGFRNovel monoclonal antibodyClinical outcomesPoor prognosisTreatment of cancerRadiation therapySolid tumorsEpithelial cancersTumor proliferationEGFRGrowth factorKinase inhibitorsCancerReceptor biologyAntibodiesKinase inhibitionEGF receptor